相关实验视频

Updated: Sep 9, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

转移性乳腺癌中的Anti-Her2治疗模式 - 现实数据表明治疗不足

Kathrine F Vandraas^1,2,3, Sarah Hjorth^1,3, Cassia B Trewin-Nybråten⁴

¹Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.

International journal of cancer

|September 2, 2025

概括

实践数据显示,HER2+转移性乳腺癌 (mBC) 的抗HER2疗法符合建议. 然而,大量患者,特别是患有并发症的老年患者,没有接受向治疗,这表明可能治疗不足.

科学领域:

癌症学
药理学
公共卫生

背景情况:

对转移性乳腺癌 (mBC) 的抗HER2疗法的有效性已在临床试验中确定.
关于抗HER2治疗模式和遵守mBC指南的现实数据是有限的.
了解弱势患者群体的治疗差异对于公平护理至关重要.

研究的目的:

在挪威评估HER2阳性mBC患者的抗HER2治疗模式.
评估对抗HER2疗法的国家治疗建议的遵守.
在特定的患者小组中确定影响治疗决策和潜在治疗不足的因素.

主要方法:

2012年至2021年挪威人口登记册的回顾性分析.
包括715名被诊断为HER2阳性的mBC患者.
检查抗HER2治疗序列,治疗持续时间和患者特征.

主要成果:

抗HER2治疗模式通常与国家建议一致.
常见的第一线疗法是trastuzumab和pertuzumab (55%),其次是trastuzumab单一疗法 (41%).
28% 的患者没有接受抗HER2治疗,年龄较大和并发症是重要因素; 15% 的符合条件的患者 (≤ 75 岁,健康) 治疗不足.

结论:

挪威的实际抗HER2治疗模式反映了国家指导方针.
患者的特征,特别是年龄和并发症,显著影响治疗决策.
显著比例的HER2阳性mBC患者可能未得到治疗,这凸显了对接入和护理的持续评估的需要.

关键词:

HER2+ 转移性乳腺癌基于人口的队列现实世界数据易受伤害的患者群

更多相关视频

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...